Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Feb:20:6-8.
doi: 10.1016/j.msard.2017.12.009. Epub 2017 Dec 18.

Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment

Stefania Barone  1 , Sara Scannapieco  1 , Carlo Torti  2 , Enrica Filippelli  1 , Vincenzo Pisani  2 , Alfredo Granata  1 , Domenico Console  3 , Giulio Demonte  1 , Tiziana Tallarico  1 , Serena Polidoro  1 , Aldo Quattrone  4 , Paola Valentino  5
Affiliations
Case Reports

Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment

Stefania Barone et al. Mult Scler Relat Disord. 2018 Feb.

Abstract

The anti-CD52 monoclonal antibody alemtuzumab is a highly active treatment for multiple sclerosis (MS) causing rapid depletion of B and T lymphocytes with nadir one month after last infusion. Opportunistic Cytomegalovirus (CMV) infections have been reported in MS patients treated with this drug. We report one patient who developed a CMV reactivation with hepatic involvement three weeks after the first cycle of alemtuzumab. This patient, promptly diagnosed and treated, achieved a complete recovery with valganciclovir. The possibility of this treatable opportunistic infection should be considered by neurologists in febrile patients with hepatic markers alteration after treatment with alemtuzumab.

Keywords: Alemtuzumab; CMV reactivation; Cytomegalovirus; Hepatic microabscesses; Multiple sclerosis; Opportunistic CMV infection.

PubMed Disclaimer

Publication types